The pharmaceutical firm more than doubled the size of its Boehringer Ingelheim Venture Fund, which has scored exits in two nine-figure acquisitions.
Germany-based pharmaceutical firm Boehringer Ingelheim today provided another €150m for its corporate venturing vehicle, Boehringer Ingelheim Venture Fund (BIVF), taking its total size to €250m ($300m).
BIVF was founded in 2010, and committed $130m to invest in US-based startups when it opened its first office in the country in Cambridge, Massachusetts three years later. The latest funding injection comes as it prepares to launch a second office on the west coast of the US.
Portfolio companies initially receive between…
